MoonLake Immunotherapeutics (MLTX) Financials: Revenue & Earnings
MLTX$12.72+0.41 +3.33%
$1.08B
Market Cap
-3.08
P/E
5.31
Forward P/E
71
Score
MoonLake Immunotherapeutics (MLTX) Financials: Revenue & Earnings
MLTX price $12.72 +0.41 +3.33%
- Ticker
- MLTX
- Price
- $12.72
- Change
- +0.41 +3.33%
- Market cap ?
- $1.08B
- P/E ?
- -3.08
- Forward P/E ?
- 5.31
- Dividend yield ?
- 0.00%
- Beta ?
- 1.08
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 71
- Value
- 60
- Quality
- 52
- Growth
- 100
Stocklytics score rationale: value 60, quality 52, growth 100.
Financials
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 |
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of…
Earnings and financials
MoonLake Immunotherapeutics (MLTX) trades at $12.72, with a market cap of $1.08B and a trailing P/E of -3.08. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 |
Insights · Dividends · Forecast · Financials · Learn